VivaMed BioPharma teams up with Syngene International to fast-track AI-driven drug programmes
The alliance directly links VivaMed’s computational drug hypotheses with Syngene’s preclinical development capabilities
The alliance directly links VivaMed’s computational drug hypotheses with Syngene’s preclinical development capabilities
Expansion at the Oss (NL) site adds capacity and R&D capabilities, supporting the development and manufacturing of ADCs and other novel bioconjugates from First-in-Human to commercialization
TED?A9 is part of S.Biomedics’ expanding pipeline of stem-cell-based therapies, developed using the company’s proprietary targeted embryonic stem cell differentiation platform
This transaction fundamentally strengthens Scinai's CDMO platform
The initiative, delivered in collaboration with Accenture, integrates digitally enabled operating models powered by advanced analytics and AI across the company’s procurement, manufacturing, and distribution networks
Backed by a multi-hundred-million-dollar investment, the expansion underscores Sanofi’s long-term commitment to India’s thriving life sciences ecosystem
BioAsia 2026 represents a decisive shift toward execution, scale, and global competitiveness, reflecting the rapid evolution of the life sciences ecosystem
Anand Chemiceutics serves over 1,500 laboratories, hospitals, and government institutions
Subscribe To Our Newsletter & Stay Updated